BST:80CB

Stock Analysis Report

Executive Summary

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products.

Snowflake

Fundamentals

Slightly overvalued with questionable track record.


Similar Companies

Share Price & News

How has Concordia International's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

80CB

0.8%

DE Pharmaceuticals

1.4%

DE Market


1 Year Return

-89.4%

80CB

-4.8%

DE Pharmaceuticals

3.7%

DE Market


Shareholder returns

80CBIndustryMarket
7 Day0%0.8%1.4%
30 Day0%2.0%1.8%
90 Day-63.7%10.4%3.4%
1 Year-89.4%-89.4%-1.6%-4.8%7.0%3.7%
3 Yearn/a-5.3%-13.2%18.5%8.3%
5 Yearn/a-3.0%-14.9%42.2%22.9%

Price Volatility Vs. Market

How volatile is Concordia International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Concordia International undervalued compared to its fair value and its price relative to the market?

9.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Information is not available.

Information is not available.


Price To Earnings Ratio

Information is not available.

Information is not available.


Price to Earnings Growth Ratio

Information is not available.


Price to Book Ratio

Information is not available.


Next Steps

Future Growth

How is Concordia International forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-3.5%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Information is not available.

Information is not available.

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Information is not available.

Information is not available.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has Concordia International performed over the past 5 years?

-42.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Information is not available.

Information is not available.

Information is not available.


Return on Equity

Information is not available.


Return on Assets

Information is not available.


Return on Capital Employed

Information is not available.


Next Steps

Financial Health

How is Concordia International's financial position?


Financial Position Analysis

Information is not available.

Information is not available.


Debt to Equity History and Analysis

Information is not available.

Information is not available.

Information is not available.

Information is not available.


Balance Sheet

Information is not available.

Information is not available.


Next Steps

Dividend

What is Concordia International's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%1.5%markettop25%3.8%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Information is not available.

Information is not available.

Stable Dividend: Insufficient data to determine if 80CB's dividends per share have been stable in the past.

Information is not available.


Current Payout to Shareholders

Information is not available.


Future Payout to Shareholders

Information is not available.


Next Steps

Management

What is the CEO of Concordia International's salary, the management and board of directors tenure and is there insider trading?

0.5yrs

Average management tenure


CEO

Graeme Duncan (44yo)

0.6yrs

Tenure

US$1,836,765

Compensation

Mr. Graeme Neville Duncan has been the Chief Executive Officer of Concordia International Corp. since June 26, 2018 and has been its Director since 2018. Mr. Duncan Co-Founded Caspian learning, where he re ...


CEO Compensation Analysis

Information is not available.

Information is not available.


Management Age and Tenure

0.5yrs

Average Tenure

44yo

Average Age

Information is not available.


Board Age and Tenure

0.3yrs

Average Tenure

59yo

Average Age

Information is not available.


Insider Trading

Information is not available.


Recent Insider Transactions

BuyUS$197,77610 Jun 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares15,000
Max PriceUS$13.27
SellUS$79,73403 Jun 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares4,900
Max PriceUS$16.27
SellUS$2,339,51803 Jun 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares174,071
Max PriceUS$13.44
BuyUS$134,47403 Jun 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares10,200
Max PriceUS$14.06
BuyUS$102,15628 May 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares9,100
Max PriceUS$11.33
SellUS$3,40028 May 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares300
Max PriceUS$11.33
BuyUS$13,86406 May 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares900
Max PriceUS$15.40
SellUS$1,59106 May 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares100
Max PriceUS$15.91
SellUS$12,48230 Apr 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares800
Max PriceUS$15.96
BuyUS$49,10930 Apr 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares3,200
Max PriceUS$15.89
BuyUS$42,84508 Apr 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares2,700
Max PriceUS$15.87
SellUS$4,83108 Apr 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares300
Max PriceUS$16.16
BuyUS$7,127,17502 Apr 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares533,300
Max PriceUS$15.55
SellUS$3,28102 Apr 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares200
Max PriceUS$16.41
BuyUS$247,09126 Mar 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares16,500
Max PriceUS$14.98
SellUS$18,95226 Mar 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares1,200
Max PriceUS$15.79
SellUS$114,65020 Mar 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares7,200
Max PriceUS$15.93
SellUS$35,45711 Mar 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares2,200
Max PriceUS$16.28
SellUS$103,89104 Mar 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares6,300
Max PriceUS$16.54
SellUS$61,20525 Feb 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares3,700
Max PriceUS$16.58
SellUS$244,49415 Feb 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares15,000
Max PriceUS$16.42
BuyUS$105,22915 Feb 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares6,500
Max PriceUS$16.39
SellUS$271,20605 Feb 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares16,200
Max PriceUS$16.77
SellUS$61,27030 Jan 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares3,700
Max PriceUS$16.58
SellUS$113,92818 Jan 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares6,800
Max PriceUS$16.87
BuyUS$80,76014 Jan 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares4,900
Max PriceUS$16.48
SellUS$427,98602 Jan 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares25,800
Max PriceUS$16.73
BuyUS$415,08802 Jan 19
Solus Alternative Asset Management L.P.
EntityCompany
Shares25,100
Max PriceUS$16.54
SellUS$724,42421 Dec 18
Solus Alternative Asset Management L.P.
EntityCompany
Shares42,400
Max PriceUS$17.23
SellUS$308,50117 Dec 18
Solus Alternative Asset Management L.P.
EntityCompany
Shares17,800
Max PriceUS$17.46
SellUS$1,057,36512 Dec 18
Solus Alternative Asset Management L.P.
EntityCompany
Shares61,700
Max PriceUS$17.15
SellUS$164,42911 Dec 18
Solus Alternative Asset Management L.P.
EntityCompany
Shares9,900
Max PriceUS$16.75
BuyUS$167,35411 Dec 18
Solus Alternative Asset Management L.P.
EntityCompany
Shares10,500
Max PriceUS$15.94
BuyUS$62,18926 Nov 18
Solus Alternative Asset Management L.P.
EntityCompany
Shares3,700
Max PriceUS$16.81
SellUS$1,76721 Nov 18
Solus Alternative Asset Management L.P.
EntityCompany
Shares100
Max PriceUS$17.67
BuyUS$122,84621 Nov 18
Solus Alternative Asset Management L.P.
EntityCompany
Shares7,500
Max PriceUS$16.38
BuyUS$144,08113 Nov 18
Solus Alternative Asset Management L.P.
EntityCompany
Shares8,200
Max PriceUS$17.81
BuyUS$326,21806 Nov 18
Solus Alternative Asset Management L.P.
EntityCompany
Shares18,800
Max PriceUS$17.48
BuyUS$127,08231 Oct 18
Solus Alternative Asset Management L.P.
EntityCompany
Shares7,000
Max PriceUS$18.17

Ownership Breakdown


Management Team

  • Arikit Mookerjee

    MD and CFO of CPI & CLI

    • Tenure: 3.4yrs
  • Graeme Duncan (44yo)

    CEO & Director

    • Tenure: 0.6yrs
    • Compensation: US$1.84m
  • Robert Ford (51yo)

    MD & Senior Director of Legal Affairs of CPI and CLI

    • Tenure: 0yrs
  • Guy Clark

    Chief Corporate Development Officer

    • Tenure: 0.6yrs
  • Adam Peeler

    Vice President of Investor Relations & Communications

    • Tenure: 0yrs
  • Andy Hoyt

    Chief Financial Officer of US Businesses

    • Tenure: 0yrs
  • Adeel Ahmad (44yo)

    Chief Financial Officer

    • Tenure: 0.5yrs
    • Compensation: US$1.76m
  • Rob Sully

    General Counsel

    • Tenure: 0.3yrs
  • Karl Belk

    Chief Operations Officer

    • Tenure: 0.5yrs
    • Compensation: US$888.48k
  • Bryan Jacobs

    Corporate Controller

    • Tenure: 0yrs

Board Members

  • Graeme Duncan (44yo)

    CEO & Director

    • Tenure: 0.6yrs
    • Compensation: US$1.84m
  • Randy Benson (58yo)

    Non Executive Chairman of the Board

    • Tenure: 0.3yrs
  • Bob Manzo (60yo)

    Director

    • Tenure: 0.3yrs
  • Barry Fishman (61yo)

    Director

    • Tenure: 0.3yrs
  • Maurice Chagnaud

    Director

    • Tenure: 0.08yrs
  • Florian Hager

    Director

    • Tenure: 0.3yrs
  • Frances Cloud

    Director

    • Tenure: 0.08yrs

Company Information

ADVANZ PHARMA Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ADVANZ PHARMA Corp.
  • Ticker: 80CB
  • Exchange: BST
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$1.225b
  • Listing Market Cap: CA$812.866m
  • Shares outstanding: 48.91m
  • Website: https://www.advanzpharma.com

Number of Employees


Location

  • ADVANZ PHARMA Corp.
  • 277 Lakeshore Road East
  • Suite 302
  • Oakville
  • Ontario
  • L6J 1H9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
A2AMJSDB (Deutsche Boerse AG)COM NPVDECADNo data
CXRTSX (The Toronto Stock Exchange)YesLimited Voting SharesCACADDec 2013
CXRX.FOTCPK (Pink Sheets LLC)YesLimited Voting SharesUSUSDDec 2013
80CDDB (Deutsche Boerse AG)YesLimited Voting SharesDEEURDec 2013
80CBBST (Boerse-Stuttgart)YesLimited Voting SharesDEEURDec 2013

Biography

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segm ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2018/12/03 19:34
End of Day Share Price2018/09/14 00:00
Earnings2018/09/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.